ZNRF3 and prostate carcinoma: This implicates WNT signaling in the development of aggressive, potentially lethal prostate cancer, consistent with our finding—across multiple independent cohorts—of a link between ZNRF3 loss, WNT pathway activation, and adverse clinical outcomes.